| ￥9900 在线订购包邮(港澳台除外) | |
| Z06546-100 | |
|
|
|
|
|
|
|
|
|
| 咨询产品问题 | |
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 258 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%. »
| Target Background | Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. |
| Synonyms | CT83; HLA class I; MHC class I; HLA-A; HLA-A*0101; MHC; MHC HLA-A alpha |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
